Zhang Dan, Hu Xiaoming, Qian Li, Wilson Belinda, Lee Christopher, Flood Patrick, Langenbach Robert, Hong Jau-Shyong
Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.
Toxicol Appl Pharmacol. 2009 Jul 1;238(1):64-70. doi: 10.1016/j.taap.2009.04.015. Epub 2009 May 3.
Microglial activation has been implicated in many astrogliosis-related pathological conditions including astroglioma; however, the detailed mechanism is not clear. In this study, we used primary enriched microglia and astrocyte cultures to determine the role of microglial prostaglandin E(2) (PGE(2)) in the proliferation of astrocytes. The proliferation of astrocytes was measured by BrdU incorporation. The level of PGE(2) was measured by ELISA method. Pharmacological inhibition or genetic ablation of COX-2 in microglia were also applied in this study. We found that proliferation of astrocytes increased following lipopolysaccharide (LPS) treatment in the presence of microglia. Furthermore, increased proliferation of astrocytes was observed in the presence of conditioned media from LPS-treated microglia. The potential involvement of microglial PGE(2) in enhanced astrocyte proliferation was suggested by the findings that PGE(2) production and COX-2 expression in microglia were increased by LPS treatment. In addition, activated microglia-induced increases in astrocyte proliferation were blocked by the PGE(2) antagonist AH6809, COX-2 selective inhibitor DuP-697 or by genetic knockout of microglial COX-2. These findings were further supported by the finding that addition of PGE(2) to the media significantly induced astrocyte proliferation. These results indicate that microglial PGE(2) plays an important role in astrocyte proliferation, identifying PGE(2) as a key neuroinflammatory molecule that triggers the pathological response related to uncontrollable astrocyte proliferation. These findings are important in elucidating the role of activated microglia and PGE(2) in astrocyte proliferation and in suggesting a potential avenue in the use of anti-inflammatory agents for the therapy of astroglioma.
小胶质细胞活化与包括星形细胞瘤在内的许多与星形胶质细胞增生相关的病理状况有关;然而,具体机制尚不清楚。在本研究中,我们使用原代富集的小胶质细胞和星形胶质细胞培养物来确定小胶质细胞前列腺素E(2)(PGE(2))在星形胶质细胞增殖中的作用。通过BrdU掺入法测量星形胶质细胞的增殖。通过ELISA法测量PGE(2)的水平。本研究还应用了小胶质细胞中COX-2的药理学抑制或基因敲除。我们发现,在有小胶质细胞存在的情况下,脂多糖(LPS)处理后星形胶质细胞的增殖增加。此外,在存在来自LPS处理的小胶质细胞的条件培养基时,观察到星形胶质细胞的增殖增加。LPS处理增加了小胶质细胞中PGE(2)的产生和COX-2的表达,这一发现提示小胶质细胞PGE(2)可能参与增强星形胶质细胞的增殖。此外,PGE(2)拮抗剂AH6809、COX-2选择性抑制剂DuP-697或小胶质细胞COX-2基因敲除可阻断活化的小胶质细胞诱导的星形胶质细胞增殖增加。向培养基中添加PGE(2)可显著诱导星形胶质细胞增殖,这一发现进一步支持了上述结果。这些结果表明,小胶质细胞PGE(2)在星形胶质细胞增殖中起重要作用,确定PGE(2)为触发与不可控星形胶质细胞增殖相关病理反应的关键神经炎症分子。这些发现对于阐明活化的小胶质细胞和PGE(2)在星形胶质细胞增殖中的作用以及为星形细胞瘤治疗提出抗炎药物的潜在应用途径具有重要意义。